Xilio Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of XTX501

Article summary

Xilio Therapeutics has initiated dosing in its Phase 1/2 clinical trial for XTX501, a bispecific antibody fusion protein targeting metastatic non-small cell lung cancer.